Spark Therapeutics Sees Promise in Phase 3 Data for Drug Candidate

Spark Therapeutics has presented positive results for its drug candidate voretigene neparvovec for the potential treatment of inherited retinal disease.

Spark Therapeutics reported that the drug’s durability of benefit was maintained for at least two years. In Phase 3 studies, company officials reported that 93 percent of subjects responded to the drug.

Voretigene neparvovec has received both breakthrough therapy and orphan product designations from the FDA and orphan product designation from the EMA.